Dyax’ proprietary drug discovery technology is used to identify antibody, small protein and peptide compounds for clinical development. For example, Dyax identified its lead product candidate DX-88, and other compounds in its pipeline, using the phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets.
Under the terms of the agreement, Dyax will receive technology license fees from Icos, as well as clinical milestone payments and royalties on net sales of any products that may result from Icos’ use of the Dyax libraries.
The agreement provides Icos with a license to Dyax’ antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax’ technology.